AGM/EGMMay 12, 2026, 04:27 PM
X4 Pharmaceuticals Stockholders Approve Equity Plan, Elect Directors
AI Summary
X4 Pharmaceuticals, Inc. announced the final results of its Annual Meeting of Stockholders. Stockholders elected three Class III director nominees, ratified PricewaterhouseCoopers LLP as the independent auditor for 2026, and approved the Second Amended and Restated 2017 Equity Incentive Plan. Additionally, the non-binding advisory vote on the compensation of named executive officers was approved.
Key Highlights
- Stockholders elected Gary J. Bridger, Fran çoise De Craecker, and Michael S. Wyzga as Class III directors until the 2029 Annual Meeting.
- The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026 was ratified with 82,734,674 votes For.
- The Second Amended and Restated 2017 Equity Incentive Plan was approved with 58,679,552 votes For.
- The non-binding advisory vote on named executive officer compensation was approved with 70,932,142 votes For.
Price Impact
More from XFOR